Literature DB >> 26361828

Interplay Between Adiponectin and Pro-Atrial Natriuretic Peptide and Prognosis in Patients With ST-Segment Elevation Myocardial Infarction.

Søren Lindberg1, Jan S Jensen2, Søren Hoffmann3, Sune H Pedersen3, Allan Z Iversen3, Søren Galatius3, Jan Frystyk4, Allan Flyvbjerg4, Jens P Goetze5, Mette Bjerre4, Rasmus Mogelvang3.   

Abstract

Natriuretic peptides (NPs) may regulate adipocyte metabolism including adiponectin. Infusion of atrial natriuretic peptide (ANP) increases plasma adiponectin in patients with heart failure. However, this relation has not been examined in a clinical setting or in myocardial infarction (MI). Accordingly, we investigated the interplay between proANP and adiponectin and the prognostic implications in patients with MI. We prospectively included 680 patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention from September 2006 to December 2008. Blood samples were drawn immediately before percutaneous coronary intervention. Additionally, we included 40 patients with 4 obtained blood samples during STEMI. Adiponectin and proANP were measured in all plasma samples. All patients were followed for 5 years. End points were all-cause mortality (n = 137) and the combined end point (n = 170) of major adverse cardiovascular events (MACEs). Plasma adiponectin and proANP were strongly associated at admission (r = 0.34, p <0.001). In patients with increasing proANP during STEMI, adiponectin also increased (0.5 ± 0.3 vs -0.1 ± 0.1 mg/L, p = 0.026). During follow-up, patients with higher adiponectin at admission had increased risk of all-cause mortality and MACE (both, p <0.001). After adjustment for confounding risk factors by Cox regression analysis, adiponectin remained an independent predictor of all-cause mortality and MACE: hazard ratio 1.31 (95% confidence interval 1.07 to 1.60; p = 0.009) and 1.31 (95% confidence interval 1.09 to 1.57; p = 0.004), respectively, for each SD increase. However, the association vanished when proANP was included in the analysis. In conclusion, adiponectin is associated with an increased risk of all-cause mortality and MACE. However, concomitantly elevated proANP levels appear to confound the association between adiponectin and worsened outcome.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26361828     DOI: 10.1016/j.amjcard.2015.07.060

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  Obesity and cardiovascular disease in women.

Authors:  Camila Manrique-Acevedo; Bhavana Chinnakotla; Jaume Padilla; Luis A Martinez-Lemus; David Gozal
Journal:  Int J Obes (Lond)       Date:  2020-02-17       Impact factor: 5.095

2.  The Adiponectin Paradox for All-Cause and Cardiovascular Mortality.

Authors:  Claudia Menzaghi; Vincenzo Trischitta
Journal:  Diabetes       Date:  2018-01       Impact factor: 9.461

3.  Comorbidity burden may explain adiponectin's paradox as a marker of increased mortality risk in hemodialysis patients.

Authors:  Ilia Beberashvili; Tamar Cohen-Cesla; Amin Khatib; Ramzia Abu Hamad; Ada Azar; Kobi Stav; Shai Efrati
Journal:  Sci Rep       Date:  2021-04-27       Impact factor: 4.379

4.  Left Atrial Volume Index to Left Ventricular Ejection Fraction Ratio Predicted Major Adverse Cardiovascular Event in ST-Elevated Myocardial Infarction Patients during 8 Years of Follow-up.

Authors:  Ahmet Seyda Yilmaz; Fatih Kahraman; Elif Ergül; Mustafa Çetin
Journal:  J Cardiovasc Echogr       Date:  2022-01-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.